Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

April 19, 2015 3:54 PM ET


Company Overview of Salix Pharmaceuticals, Inc.

Company Overview

Salix Pharmaceuticals, Inc. is a specialty pharmaceutical company that focuses on developing, marketing, and licensing prescription pharmaceutical products for the prevention and treatment of gastrointestinal disorders. It sells its products to healthcare professionals through its direct sales force in the United States. The company was founded in 1989 and is based in Raleigh, North Carolina. Salix Pharmaceuticals, Inc. operates as a subsidiary of Salix Pharmaceuticals Ltd.

8510 Colonnade Center Drive

Raleigh, NC 27615

United States

Founded in 1989





Key Executives for Salix Pharmaceuticals, Inc.

Chairman of the Board and Acting Chief Executive Officer
Age: 70
Age: 59
Acting Chief Financial Officer and Senior Vice President of Finance & Administrative Services
Age: 53
Acting Chief Operating Officer
Age: 49
Chief Development Officer and President of Medical, Research & Development
Age: 52
Compensation as of Fiscal Year 2014.

Salix Pharmaceuticals, Inc. Key Developments

Napo Pharmaceuticals, Inc. Files Brief on Appeal in Dispute with Salix Pharmaceuticals, Inc

Napo Pharmaceuticals, Inc. announced that it has filed its opening brief in the Appellate Division of the Supreme Court of the State of New York seeking to reverse the December 2013 Order of the Supreme Court of the State of New York that prevented important claims from being tried to verdict by a jury in the Napo vs. Salix Pharmaceuticals, Inc. litigation. Napo filed a lawsuit against the company in New York on May, 2011 seeking to terminate its December 9, 2008 Collaboration Agreement with Salix for the Development, Manufacture and Commercialization of Napo's first-in-class anti-diarrheal drug, crofelemer. Napo's original complaint alleged that the company had materially breached its contract with Napo by its failure to use commercially reasonable efforts to develop crofelemer. Napo's appeal includes a challenge to the lower court decision that the company's decision to withhold investment in commercial manufacturing capacity sufficient to launch crofelemer upon FDA approval was reasonable. The issues on appeal include the lower court's ruling that Salix was entitled to ignore its obligations to commercialize and develop other indications for crofelemer as required by the Collaboration Agreement, including specifically diarrhea predominant irritable bowel syndrome, an indication for which the company has licensed worldwide rights. Other licensed indications include pediatric, acute infectious (including cholera), and chemotherapy-related diarrheas. In December, 2012, the US Food and Drug Administration approved crofelemer for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. The Appeal also cites the company's delay in obtaining FDA approval of FULYZAQ, especially in light of the announcement of positive Phase 3 trial results in November, 2010. Crofelemer had previously received Fast Track designation from the FDA for this indication.

Lupin Ltd Enters into an Exclusive Deal to Market Some Products of Salix Pharmaceuticals Inc

Lupin Ltd. announced that it has entered into an exclusive deal to market some products of Salix Pharmaceuticals Inc. in Canada, in a move to expand its footprint in that region. Lupin will get an upfront payment from Salix, and is entitled to additional payments contingent on meeting some sales milestones. Lupin has the option to sell other gastroenterology products in Salix's pipeline after approval by Canadian regulators. The deal includes Salix's Relistor injection for the treatment of opioid-induced constipation, and Zaxine for use in adults to help reduce risk of recurrence of overt hepatic encephalopathy - a disorder that causes worsening of brain function.

Similar Private Companies By Industry

Company Name Region
Honey Naturals LLC United States
BioValve Technologies, Inc. United States
Cebert Pharmaceuticals, Inc. United States
Vertical Pharmaceuticals, LLC United States
Jason Properties, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Salix Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at